A review of the positive and negative effects of cardiovascular drugs on sexual function: A proposed table for use in clinical practice

Netherlands Heart Journal

Volumn 22, Issue 1, 2014, Pages 11-19

  Nicolai, M P J ^a   Liem, S S ^b   Both, S ^a   Pelger, R C M ^a   Putter, H ^a   Schalij, M J ^a   Elzevier, H W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMSTELLAND HOSPITAL   (Netherlands)

Author keywords

Adrenergic beta antagonists; Angiotensin receptor antagonists; Angiotensin converting enzyme inhibitors; Calciumchannel blockers; Diuretics; Hydroxymethylglutaryl CoA reductase inhibitors; Sexualdysfunction

Indexed keywords

ACEBUTOLOL; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; CHLORTALIDONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NEBIVOLOL; PROPRANOLOL; SILODOSIN; SPIRONOLACTONE; TAMSULOSIN; TERAZOSIN; TRIAMTERENE; UNINDEXED DRUG;

BREAST TENDERNESS; CARDIOLOGIST; CLINICAL PRACTICE; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GENERAL PRACTITIONER; GYNECOMASTIA; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; LIBIDO DISORDER; PATIENT CARE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SYSTEMATIC REVIEW;

EID: 84892607245     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-013-0482-z     Document Type: Review

References (86)

1. IMS Institute for Healthcare Informatics. The use of medicines in the united states, review of 2010. Update april 2011: http://www. imshealth.com/deployedfiles/imshealth/Global/Content/IMS% 20Institute/Static%20File/IHII_UseOfMed_report.pdf.
2. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol. 2000;164(4):1188-91.
3. Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl. 1997;1:47-51.
4. Manolis A, Doumas M. Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep. 2012;14(4):285-92.
5. Nicolai MPJ, Liem SS, Both S, et al. What do cardiologists know about the effects of cardiovascular drugs on sexual function? A survey among Dutch cardiologists. Neth Heart J. 2013.
6. Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14(1):27-31.
7. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep. 2002;4(3):202-10.
8. Bauer GE, Baker J, Hunyor SN, et al. Side-effects of antihypertensive treatment: a placebo-controlled study. Clin Sci Mol Med Suppl. 1978;4:341s-4s.
9. Suzuki H, Tominaga T, Kumagai H, et al. Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens Suppl. 1988;6(4):S649-51.
10. Barksdale JD, Gardner SF. The impact of first-line antihypertensive drugs on erectile dysfunction. Pharmacotherapy. 1999;19(5):573-81.
11. Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol. 2002;58(3):177-80.
12. Franzen D, Metha A, Seifert N, et al. Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res. 2001;13(6):348-51.
13. Perez-Stable EJ, Halliday R, et al. The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension. Am J Med. 2000;108(5):359-65.
14. Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24(21):1928-32.
15. Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med. 1991;114(8):613-20.
16. Doumas M, Tsiodras S, Tsakiris A, et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24(12):2387-92.
17. Ma R, Yu J, Xu D, et al. Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. J Hypertens. 2012;30(1):210-6.
18. Fogari R, Preti P, Zoppi A, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens. 2004;17(1):77-81.
19. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351-7.
20. Erdmann E. Safety and tolerability of beta-blockers: prejudices & reality. Indian Heart J. 2010;62(2):132-5.
21. Heart Foundation. Guide to management of hypertension 2008-2010. [http://www.heartfoundation.org.au/SiteCollectionDocuments/ HypertensionGuidelines2008to2010Update.pdf]. 2012.
22. Hackett G, Kell P, Ralph D, et al. British Society for SexualMedicine guidelines on the management of erectile dysfunction. J Sex Med. 2008;5(8):1841-65.
23. Karavitakis M, Komninos C, Theodorakis PN, et al. Evaluation of sexual function in hypertensive men receiving treatment: a review of current guidelines recommendation. J Sex Med. 2011;8(9):2405-14.
24. Doumas M, Tsakiris A, Douma S, et al. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl. 2006;8(2):177-82.
25. Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther. 2009;31(3):447-62.
26. Brixius K, Middeke M, Lichtenthal A, et al. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol. 2007;34(4):327-31.
27. Baumhakel M, Schlimmer N, Kratz M, et al. Cardiovascular risk, drugs and erectile function-a systematic analysis. Int J Clin Pract. 2011;65(3):289-98.
28. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs. 2005;65(6):773-86.
29. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981 Sep 12;2(8246):539-43.
30. Grimm Jr RH, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29(1 Pt 1):8-14.
31. Bulpitt CJ, Dollery CT. Side effects of hypotensive agents evaluated by a self-administered questionnaire. Br Med J. 1973;3(5878): 485-90.
32. Chang SW, Fine R, Siegel D, et al. The impact of diuretic therapy on reported sexual function. Arch Intern Med. 1991;151(12):2402-8.
33. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21(8): 1563-74.
34. Duncan L, Bateman DN. Sexual function in women. Do antihypertensive drugs have an impact? Drug Saf. 1993;8(3):225-34.
35. Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011;13(9):644-8.
36. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17.
37. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21.
38. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs. 2006;66(3):287-301.
39. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003 Aug;170(2 Pt 1):530-47.
40. Hellstrom WJ, Giuliano F, Rosen RC. Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment. Urology. 2009;74(1):15-21.
41. Gupta S, Salimpour P, SaenzdeTejada I, et al. A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity. J Urol. 1998;159(5):1529-36.
42. Stoffer SS, Hynes KM, Jiang NS, et al. Digoxin and abnormal serum hormone levels. JAMA. 1973;225(13):1643-4.
43. Neri A, Zukerman Z, Aygen M, et al. The effect of long-term administration of digoxin on plasma androgens and sexual dysfunction. J Sex Marital Ther. 1987;13(1):58-63.
44. Bellmann O, Ochs HR, Knuchel M, et al. Evaluation of the hypothalamic-pituitary effects of digoxin. J Clin Pharmacol. 1984;24(11-12):474-9.
45. Kley HK, Abendroth H, Hehrmann R, et al. No effect of digitalis on sex and adrenal hormones in healthy subjects and in patients with congestive heart failure. Klin Wochenschr. 1984;62(2):65-73.
46. Kley HK, Muller A, Peerenboom H, et al. Digoxin does not alter plasma steroid levels in health men. Clin Pharmacol Ther. 1982;32(1):12-7.
47. Fogari R, Zoppi A, Corradi L, et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens. 1998;11(10):1244-7.
48. Baumhakel M, Schlimmer N, Bohm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res. 2008;20(5):493-500.
49. Rastogi S, Rodriguez JJ, Kapur V, et al. Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem. Int J Impot Res. 2005;17 Suppl 1:S25-36.
50. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94(3):258-65.
51. Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl. 2003;2:29-34.
52. Becker AJ, Uckert S, Stief CG, et al. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology. 2001;57(1):193-8.
53. Baumhakel M, Custodis F, Schlimmer N, et al. Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. J Pharmacol Exp Ther. 2008;327(3):692-8.
54. Kroner BA, Mulligan T, Briggs GC. Effect of frequently prescribed cardiovascular medications on sexual function: a pilot study. Ann Pharmacother. 1993;27(11):1329-32.
55. Bohm M, Baumhakel M, Teo K, et al. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation. 2010;121(12):1439-46.
56. Viigimaa M, Doumas M, Vlachopoulos C, et al. Hypertension and sexual dysfunction: time to act. J Hypertens. 2011;29(2):403-7.
57. Segal RL, Bivalacqua TJ, Burnett AL. Irbesartan promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective long-term analysis. BJU Int. 2012;110(11):1782-6.
58. Chen Y, Cui S, Lin H, et al. Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res. 2012;24(6):217-20.
59. Kochar MS, Mazur LI, Patel A. What is causing your patient's sexual dysfunction? Uncovering a connection with hypertension and antihypertensive therapy. Postgrad Med. 1999;106(2):149-7.
60. Ogihara T, Kuramoto K. Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. NICS-EH Study Group. National Intervention Cooperative Study in Elderly Hypertensives. Hypertens Res. 2000;23(1):33-7.
61. Omvik P, Thaulow E, Herland OB, et al. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens. 1993;11(1):103-13.
62. Kroner BA, Mulligan T, Briggs GC. Effect of frequently prescribed cardiovascular medications on sexual function: a pilot study. Ann Pharmacother. 1993;27(11):1329-32.
63. Tanner LA, Bosco LA. Gynecomastia associated with calcium channel blocker therapy. Arch Intern Med. 1988;148(2):379-80.
64. Azzarito C, Boiardi L, Vergoni W, et al. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm Metab Res. 1996;28(4):193-8.
65. Hyyppa MT, Kronholm E, Virtanen A, et al. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology. 2003;28(2):181-94.
66. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418.
67. Smals AG, Weusten JJ, Benraad TJ, et al. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity. J Steroid Biochem Mol Biol. 1991;38(4):465-8.
68. Andreis PG, Cavallini L, Mazzocchi G, et al. Effects of prolonged administration of lovastatin, an inhibitor of cholesterol synthesis, on the morphology and function of rat Leydig cells. Exp Clin Endocrinol. 1990;96(1):15-24.
69. Solomon H, Samarasinghe YP, Feher MD, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract. 2006;60(2):141-5.
70. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol. 2004;172(1):255-8.
71. Dogru MT, Basar MM, Simsek A, et al. Effects of statin treatment on serum sex steroids levels and autonomic and erectile function. Urology. 2008;71(4):703-7.
72. Trivedi D, Kirby M, Wellsted DM, et al. Can simvastatin improve erectile function and health-related quality of life in men aged >/=40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. BJU Int. 2013;111(2):324-33.
73. Herrmann HC, Levine LA, Macaluso J, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med. 2006;3(2):303-8.
74. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol. 2004;172(1):255-8.
75. Castro MM, Rizzi E, Rascado RR, et al. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol. 2004;498(1-3):189-94.
76. Dadkhah F, Safarinejad MR, Asgari MA, et al. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res. 2010;22(1):51-60.
77. Haendeler J, Hoffmann J, Zeiher AM, et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation. 2004;110(7):856-61.
78. Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med. 2004;37(12):2064-71.
79. Sinzinger H, Chehne F, Lupattelli G. Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy. Drug Saf. 2002;25(12):877-83.
80. Trivedi D, Kirby M, Wellsted DM, et al. Can simvastatin improve erectile function and health-related quality of life in men aged >/=40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. BJU Int 2012 Jun 11.
81. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005;96(2):313-21.
82. Della CA, Pfiffner D, Meier B, et al. Sexual activity in hypertensive men. J Hum Hypertens. 2003;17(8):515-21.
83. Doumas M, Douma S. The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens (Greenwich). 2006;8(5):359-64.
84. McLaughlin T, Harnett J, Burhani S, et al. Evaluation of erectile dysfunction therapy in patients previously nonadherent to long-term medications: a retrospective analysis of prescription claims. Am J Ther. 2005;12(6):605-11.
85. Fogari R, Preti P, Zoppi A, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens. 2004;17(1):77-81.
86. Nicolai MP, Both S, Liem SS, et al. Discussing sexual function in the cardiology practice. Clin Res Cardiol 2013 Feb 8.